Persistent spinal pain has become one of the most burdensome musculoskeletal conditions worldwide, and the therapeutic industry built around it is expanding just as steadily. CLBP full form stands for Chronic Lower Back Pain — pain localized to the lower back that lasts 12 weeks or longer, often continuing well past the expected healing window….

The intratumoral cancer therapies market is entering a phase of rapid expansion. Valued at roughly USD 115 million across the seven major markets (US, EU4, UK, and Japan) in 2025, this space is projected to surge to nearly USD 4.19 billion by 2034, reflecting a compound annual growth rate above 49%. Few segments in oncology…

The glucagon like peptide 1 agonist market has moved well beyond its original role in type 2 diabetes management. What began as a glucagon therapy market niche has evolved into one of pharma’s fastest-growing categories, now spanning obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH). Two companies, Eli…

The Obesity Market has entered one of its most transformative phases in decades, propelled by the rise of incretin-based therapies and a growing recognition of obesity as a chronic disease requiring sustained pharmacological management. Across the seven major markets (the US, EU4, UK, and Japan), the treatment landscape is shifting rapidly from lifestyle-only interventions toward…

Type 2 Diabetes is a chronic metabolic disorder marked by insulin resistance and progressive ß-cell dysfunction, leading to persistent hyperglycemia. Unlike type 1 diabetes, it develops primarily from impaired insulin action, initially compensated by increased insulin secretion until ß-cell failure occurs. Its global rise is driven by aging populations and lifestyle changes such as physical…

The chronic pain market across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — was valued at approximately USD 12 billion in 2025 and is projected to grow at a CAGR of 5.1% through 2036. This steady expansion is being driven by the anticipated entry of…

The CKD market across the seven major markets (7MM) — the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan — stood at roughly USD 5 billion in 2025, with continued growth projected through 2036. This valuation reflects the current treatment landscape, which spans erythropoietin stimulating agents, ACE inhibitors, ARBs, antidiabetic drugs, secondary hyperparathyroidism…

Progeria is an ultra-rare group of genetic disorders marked by dramatically accelerated aging, and interest in the progeria drug market continues to build as awareness grows and research investment increases. Although no cure exists today, the disease’s visibility among clinicians, patient advocacy groups, and pharmaceutical developers has steadily expanded, shaping a market that is small…

The exosome therapy market is entering a pivotal decade. These cell-free, nanoscale vesicles carry proteins, lipids, and RNA between cells, giving researchers a way to modulate disease processes without the risks tied to live-cell therapies. Though no exosome-based product has reached full approval yet, a growing late-stage pipeline suggests that could change soon, with the…

The Non-small cell lung cancer market has become one of the most closely watched segments within oncology, driven by a wave of targeted therapies, immunotherapies, and antibody-drug conjugates entering the treatment landscape. As the most common form of lung cancer, accounting for roughly 85% of all cases, non-small cell lung cancer (NSCLC) continues to attract…